Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers
CLDN18.2 is not expressed in normal prostate tissue or PC, suggesting that it is unlikely to serve as a prognostic marker or a potential target for immunotherapy in PC.
Authors
- Mi Jin Gu (ORCID: https://orcid.org/0000-0002-8350-3038)
- Young-Mog Shim
- Jin-A Baek (ORCID: https://orcid.org/0000-0001-6326-0828)
Institutions
- Bristol-Myers Squibb (South Korea) (KR)
- Yeungnam University College
- Yeungnam University (KR)
Publication Details
- Journal
- In Vivo
- Published
- 2025-02-26
- DOI
- https://doi.org/10.21873/invivo.13884
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00